GSKGlaxoSmithKlineRunning, no new patients
China Subpopulation: Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
Multiple Myeloma
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 72 (final count)
- Started
- Jul 28, 2021
- Main results expected
- Apr 3, 2024
- Fully finished
- Jun 30, 2028
- Results posted
- Apr 23, 2025
What counts as success
The trial's main goal(s), called the “primary outcome.”
Progression-free Survival (PFS)
Measured over: Up to approximately 32 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT06868654 · record last updated 2026-04-23 · checked 2026-11-09 15:47 UTC